Sonnet BioTherapeutics Holdings, Inc. financial data

Location
Princeton, NJ
Fiscal year end
30 September
Latest financial report
10-K - Q3 2025 - 16 Dec 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 166% % 14%
Debt-to-equity 125% % -20%
Return On Assets -229% % -53%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6,754,352 shares 30%
Common Stock, Shares, Outstanding 7,077,352 shares 988%
Entity Public Float $4,150,174 USD -91%
Common Stock, Value, Issued $708 USD 989%
Weighted Average Number of Shares Outstanding, Basic 4,081,296 shares 523%
Weighted Average Number of Shares Outstanding, Diluted 4,081,296 shares 523%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $1,000,000 USD 5269%
Research and Development Expense $8,355,304 USD 46%
General and Administrative Expense $8,488,811 USD 38%
Operating Income (Loss) $15,844,115 USD -34%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $15,793,087 USD -112%
Income Tax Expense (Benefit) $158,400 USD
Net Income (Loss) Attributable to Parent $16,011,487 USD -115%
Earnings Per Share, Basic -3.95 USD/shares 65%
Earnings Per Share, Diluted -3.95 USD/shares 65%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $5,120,264 USD 3326%
Accounts Receivable, after Allowance for Credit Loss, Current $500,000 USD
Assets, Current $14,342,726 USD 577%
Property, Plant and Equipment, Net $10,906 USD -47%
Operating Lease, Right-of-Use Asset $43,775 USD -65%
Other Assets, Noncurrent $487,151 USD -1.4%
Assets $14,884,558 USD 437%
Accounts Payable, Current $2,942,331 USD 35%
Liabilities, Current $4,096,979 USD 28%
Operating Lease, Liability, Noncurrent $23,634 USD -79%
Liabilities $4,096,979 USD 26%
Retained Earnings (Accumulated Deficit) $133,692,472 USD -14%
Stockholders' Equity Attributable to Parent $10,787,579 USD
Liabilities and Equity $14,884,558 USD 437%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,910,246 USD 5.9%
Net Cash Provided by (Used in) Financing Activities $7,622,293 USD 99%
Common Stock, Shares Authorized 125,000,000 shares 0%
Common Stock, Shares, Issued 7,077,352 shares 988%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,712,047 USD 531%
Deferred Tax Assets, Valuation Allowance $39,644,696 USD 8.7%
Deferred Tax Assets, Gross $39,659,354 USD 8.6%
Operating Lease, Liability $46,573 USD -64%
Depreciation $3,211 USD 0%
Lessee, Operating Lease, Liability, to be Paid $48,216 USD -66%
Operating Lease, Liability, Current $46,573 USD -45%
Lessee, Operating Lease, Liability, to be Paid, Year Two $48,216 USD -50%
Lessee, Operating Lease, Liability, to be Paid, Year One $48,216 USD -50%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,643 USD -87%
Deferred Tax Assets, Operating Loss Carryforwards $29,195,207 USD 9.1%
Preferred Stock, Shares Issued 7,500 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Additional Paid in Capital $144,479,342 USD 23%
Preferred Stock, Shares Outstanding 7,500 shares
Deferred Tax Assets, Net of Valuation Allowance $14,658 USD -63%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%